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Abstract: Injury to the central nervous system initiates complex physiological, cellular and 
molecular processes that can result in neuronal cell death. Of interest to this review is the 
activation of the kinin family of neuropeptides, in particular bradykinin and substance P. 
These neuropeptides are known to have a potent pro-inflammatory role and can initiate 
neurogenic inflammation resulting in vasodilation, plasma extravasation and the 
subsequent development of edema. As inflammation and edema play an integral role in the 
progressive secondary injury that causes neurological deficits, this review critically 
examines kinin receptor antagonists as a potential neuroprotective intervention for acute 
brain injury, and more specifically, traumatic brain and spinal cord injury and stroke. 
Keywords: brain injury; neurotrauma; stroke; neuropeptides; kinins 
 
1. Introduction  
Injuries to the central nervous system (CNS) initiate a complex cascade of secondary biochemical 
and molecular events that can exacerbate the initial primary injury and the resultant neurological 
deficits [1]. The primary injury is amenable only to interventions that reduce the risk of insult 
occurring, whereas the secondary phase of injury can potentially be reduced with pharmacological 
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reagents that target the secondary injury factors. Many factors that contribute to the secondary phase of 
injury have been identified including blood-brain barrier (BBB) disruption, edema formation, release 
of neurotoxic excitatory amino acids, oxidative stress and apoptosis, amongst others. The concept of 
neuroprotection is based on developing appropriate pharmacological interventions that attenuate these 
secondary processes and improve the functional outcome of patients. The ability of pharmacological 
agents to limit the biochemical neurotoxicity and secondary cell death has been well established in 
numerous animal models of traumatic brain injury (TBI), spinal cord injury (SCI) and stroke. However, 
the results of such neuroprotective strategies have so far produced disappointing outcomes in clinical 
trials. While the reason for these failures is multifactorial, it is also clear that the targeting of a single 
factor is of limited benefit when so many different factors contribute to the injury cascade. On the 
other hand, if a target could be identified that has modulatory effects on multiple injury factors, this 
target could theoretically provide a multipotential therapeutic approach. One such target is the kinin 
family of neuropeptides that have been shown to be important modulators of acute CNS injury through 
multiple mechanisms.  
2. Kinins and Their Receptors 
All components of the kinin system have been found in abundance throughout both the rat and 
human CNS, and have attracted interest in neuroprotective research due to their pro-inflammatory 
action and integral role in initiating neurogenic inflammation following certain types of injury or 
infection. Of the kinins, bradykinin and substance P (SP) are thought to be the most potent modulators 
of these injury mechanisms and thus have received the most attention.  
There are two major kinin families: the slow acting bradykinins and the fast acting tachykinins. The 
bradykinin family includes bradykinin and Lys-bradykinin, also known as kallidin, which are formed 
by proteolytic cleavage of the protein precursor, kininogen, by plasma and tissue proteases known as 
kallikreins [2,3]. These kinins bind to the two bradykinin receptors, the constitutively expressed B2 
receptor and the B1 receptor whose expression is low in normal conditions but is upregulated 
following injury, infection and inflammation. In particular, release of cytokines such as interleukin-1β 
(IL-1β) and tumour necrosis factor-α (TNF-α) are potent modulators of B1 receptor expression [4]. 
Unlike the B2 receptor, which is activated by both bradykinin and kallidin, the B1 receptor 
preferentially binds Lys-des-Arg9-bradykinin, or bradykinin or kallidin which have had the C-terminal 
Arg removed by kinases, carboxypeptidase N (in tissue) or carboxypeptidase M (associated with cell 
membranes) [5]. Once bradykinin has bound to the B2 receptor, the receptor/ligand complex is rapidly 
internalized before being desensitized and the receptor recycled to the cell surface. In contrast, the B1 
receptor and its ligand is slowly internalized and does not undergo desensitization [5].  
The tachykinin family includes the neuropeptides SP, neurokinin A (NKA) and neurokinin B 
(NKB), which are located in capsaicin-sensitive neurons, also known as primary sensory neurons, 
within the CNS, peripheral tissue and non-neuronal cells including endothelial and inflammatory cells  
[6]. Tachykinins share a common terminal sequence that is essential for their biological activity and 
thus there is a certain amount of cross reactivity among the tachykinin receptors and their ligands [7,8]. 
SP has greatest affinity for the tachykinin-1 (NK1) receptor whereas NKA and NKB preferentially 
bind to the tachykinin-2 (NK2) and tachykinin-3 (NK3) receptor, respectively [9]. Like bradykinin, 




once SP binds to the NK1 receptor, the receptor and its ligand are rapidly internalized and 
desensitized [10]. SP expression is most prominent in brain and nerves, although mRNA for other 
neurokinin receptors is detectable in many cells and regions. However, the predominance of the NK1 
receptor in the human adult brain [11] makes SP the main tachykinin of interest in the pathophysiology 
of CNS injury.  
Kinin receptors are found throughout the CNS, where they are expressed on neurons, astrocytes, 
microglia, endothelial cells and oligodendrocytes [12–15]. They belong to the family of G-protein 
coupled receptors and consist of 7 hydrophobic transmembrane domains [4,10]. Activation of kinin 
receptors stimulates membrane phospholipid metabolism. Once bound to its respective receptor, both 
bradykinin and SP activates the G-protein coupled to phospholipase C (PLC), which then converts 
phosphotidylinositol-4-5-biphosphate to 1,2,5-triphosphate (IP3) and diaglycerol (DAG) [16–18]. This 
rise in both IP3 and DAG occurs within seconds following ligand binding and results in a subsequent 
rise in intracellular calcium (Ca2+). This increase in Ca2+ is the key to initiation of many secondary 
messenger systems in all cells, including the activation of protein kinase C (PKC) and the release of 
other neurotransmitters (Figure 1).  
Downstream effects of kinin receptor ligand binding also involves the release of arachidonic acid 
from membrane phospholipids through both a direct activation of phospholipase A2 (PLA2), as well by 
the elevated Ca2+ induced activation of PLA2 and DAG lipase [4]. Arachidonic acid is then 
metabolized by prostaglandin H (PGH) synthase to prostaglandins and reactive oxygen species (ROS) 
[19], thereby initiating inflammation and contributing to oxidative stress. In addition, prostaglandins 
mediate levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP), both of which are important in modulating neuronal activity. Although it is not entirely 
known how prostaglandins do this, it is postulated that they increase cGMP by activating guanylate 
cyclase [19]. They may also impede vascular autoregulation at sites of tissue injury [20] as increased 
cGMP levels results in vasodilation and altered ion channel permeability in neurons whereas cAMP 
along with Ca2+ causes contractions of vascular smooth muscle cells. Indeed, an increase in cAMP has 
been shown to increase BBB permeability  [19]. Furthermore, the NK1 receptor has a 5’ untranslated 
region containing a cAMP binding protein that responds to elevated levels of cAMP and Ca2+ by 
increasing gene transcription of SP, thereby creating positive feedback for SP [17].  
The release of nitric oxide (NO) following the binding of kinins to their receptors also contributes to 
their effects on the vasculature as NO causes both dilation and constriction of vessels. Furthermore NO 
is involved in BBB dysfunction in CNS injury through its ability to stimulate guanylate cyclase and 
increase Ca2+ [4,18]. Overall, these receptor-signaling pathways reflect the integral role that kinins 
play in CNS injury. 
It is believed that kinins are one of the first mediators of injury mechanisms at the site of the insult 
[18,21]. Substance P release is initiated by the mechanical stretch of neurons during an injurious event 
[2] whereas bradykinin is increased after CNS injury through the release of lysosomal enzymes from 
destroyed cells, which then activate kininogen to release bradykinin or kallidin. Additionally, 
extravasation of plasma or blood products can initiate Hageman factor XII, which is involved in the 
coagulation cascade, and is a potent activator of kallikrein [19].  




Figure 1. Schematic representation of kinin induced neurogenic inflammation in the 
central nervous system. 
 
BK: bradykinin; SP: substance P; NKA: neurokinin A; CGRP: calcitonin gene-related peptide; 
NK1: tachykinin-1 receptor; B1: bradykinin B1 receptor; B2: bradykinin B2 receptor; G: G-protein; 
PLC: phospholipase C; DAG: diaglycerol; IP3: 1,2,5-triphosphate; [Ca2+]i: intracellular calcium; 
PLA2: phospholipase A2; PGH synthase: prostaglandin synthase; PG: prostaglandin; ROS: reactive 
oxygen species; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; cGMP: 
cyclic guanosine monophosphate; AC: adenylate cyclase; GC: guanylate cyclase; NOS: nitric oxide 
synthase; NO: nitric oxide. Dotted line represents the same molecular cascade as the B1 / B2 
receptor pathway.  
 
Bradykinin also further potentiates the release of SP at the injury site by activating IP3 and causing 
the subsequent rise in intracellular Ca2+, a known trigger of neurotransmitter release. However in the 
terminals of the dorsal root ganglion, bradykinin acts from a distance to release SP by depolarizing the 
nerve terminal, which opens voltage-sensitive calcium channels resulting in increased intracellular 
Ca2+ and subsequent SP release [19]. 
The kinins are believed to be involved in most aspects of early neuroinflammation due to the 
expression of their receptors on most CNS inflammatory cells. Particular focus has been their role in 
the activation of microglia and astrocytes, which are major mediators of both acute and chronic CNS 
injury. Resting microglia are vital to the control of normal immune and homeostatic functions within 
the brain [22]. Normally, these resting microglia are benign to the brain, however once activated 
through injury or during removal of unwanted cellular debris, they produce inflammatory cytokines, 
glutamate and quinolinic acid, superoxide (O2-) radicals and NO [23]. The secretion of NO by 
microglia is through activation of microglial inducible nitric oxide synthase (iNOS). NO can then react 




with O2- radicals to form perioxynityrite (ONOO), a highly reactive molecule [24]. These ROS and 
reactive nitrogen species (RNS) contribute to oxidative stress induced CNS injury by causing damage 
to lipids, proteins and DNA. Both bradykinin and SP activate microglia through their respective 
receptors, thus contributing to oxidative stress mediated cell death. However, bradykinin has also been 
shown to play a protective role in the CNS by reducing lipopolysaccharide (Endotoxin: LPS) induced 
inflammation mediated neuronal death [13]. 
Activated astrocytes are also involved in CNS injury, however their role in injury is less defined 
since they secrete protective neurotrophic substances and antioxidant enzymes, as well as the injurious 
pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α. SP is integral in this proinflammatory 
role of astrocytes because once activated by SP, nuclear factor-κβ (NF-κβ) translocates to the nucleus 
to induce cytokine secretion [25,26]. Cytokines such as IL-1β can then increase astrocytic NK1 
expression creating a positive feedback between NK1, cytokine release and astrocyte activation [27]. 
Accordingly, SP has been postulated to be involved in many inflammatory diseases [10]. Importantly 
for CNS injury, NK1 antagonist treatment has been shown to reduce CNS inflammatory processes [26].  
Bradykinin has previously been shown to stimulate glutamate release from astrocytes in vitro and 
this release can mediate fast synaptic transmission and synaptic plasticity [28]. However, it can also 
induce arachidonic acid release [13] and N-methyl-D-aspartate (NMDA) receptor mediated rise in 
neuronal intracellular Ca2+ resulting in free radical production, mitochondrial damage and activation of 
proteases, endonucleases and phospholipases. This deleterious series of events, known as glutamate 
excitotoxicity, may be a significant contributor to cell death following CNS injury.  
As previously mentioned, the kinins play an integral role in initiating neurogenic inflammation, 
which is a neurally elicited local painful inflammatory response characterized by vasodilation, protein 
extravasation and subsequent edema formation [29]. Bradykinin, by binding to its B2 receptor on 
vascular endothelial cells dilates pre-capillary arteries, increases vascular permeability and causes 
plasma extravasation [4]. Bradykinin also stimulates nociceptive sensory nerve terminals thus causing 
the release of neurotransmitters SP, NKA and CGRP [18]. Although both bradykinin and SP are 
involved in neurogenic inflammation, SP is thought to be the main mediator. Like bradykinin, SP 
binding to its NK1 receptor on endothelial cells causes opening of post-capillary venular endothelial 
gaps [30] thus increasing vessel permeability, BBB breakdown and promoting plasma 
extravasation [6]. CGRP, a most potent vasodilator, increases blood flow, bringing cytokines and 
inflammatory mediators to the area [31]. However, CGRP can further potentiate SP mediated effects 
by both increasing the expression of NK1 receptors and also enhancing the bioavailability of SP by 
competing with SP for catabolism by endopeptidases [32]. 
In addition, both bradykinin and SP cause degranulation of mast cells resulting in the release of 
histamine, serotonin and inflammatory mediators, which further increase vascular permeability and 
plasma extravasation [18,33]. This loss of barrier integrity that occurs in CNS injury also allows 
peripheral immune cells to cross the once impenetrable barrier to further contribute to or even initiate 
inflammatory processes within the brain [34].  
A rapid advance in the knowledge about kinins and their functions was made possible by 
development of the non-peptide antagonists, which are able cross the BBB to bind to the receptor and 
inhibit the effects of its ligand. The first non-peptide antagonist was synthesized by Pfizer for the NK1 
receptor, and enabled researchers to study the role of SP and NK1 in disease states [10]. To date, 




Aprepitant, an oral NK1 antagonist is the only NK1 receptor antagonist that has shown potential in a 
clinical setting, where it is effective in reducing chemotherapy-induced nausea and vomiting [35]. 
However, human studies in depression and anxiety are ongoing.  
Non-peptide antagonists for bradykinin, in particular for the B2 receptor, were subsequently 
developed. These bradykinin antagonists greatly improved the knowledge of bradykinin’s role in 
injury. Previous B1 receptor antagonists had little impact on this field of research due to the induced 
nature of B1 expression [36]. To date, B2 antagonists have shown therapeutic potential for tumors, by 
simulating apoptosis in cancer cells, as well as in inflammatory diseases and septic shock [36]. 
Furthermore, the localization of the B2 receptor within the spinal cord, particularly within areas 
involved in nociception, suggest an analgesic role for B2 antagonists [37–39].  
Importantly, kinins may play an integral role in the development of CNS injury and therefore their 
respective receptor antagonists may represent novel neuroprotective therapies. Accordingly, this 
review will focus on the potential role of kinins and the potential use of their antagonists as a treatment 
for TBI, SCI and ischemic stroke. 
3. Traumatic Brain Injury 
The injury that occurs after TBI consists of two phases. The initial primary, mechanical damage that 
occurs at the time of the traumatic incident is irreversible and only amenable to preventative measures 
designed to either prevent the injury from occurring or minimizing the extent of injury (e.g., seat belts, 
helmets, airbags, etc). The primary damage is followed by a secondary phase, which is a multifactorial 
process initiated at the time of impact and evolving over the subsequent hours to days [1]. This 
secondary phase is made up of a variety of physiological, cellular and molecular responses aimed at 
restoring homeostasis. If not controlled, these processes will lead to secondary injury. Amongst the 
pathological changes, disruption of the BBB has been demonstrated in the acute post-traumatic period, 
allowing not only an increase in intracranial pressure (ICP), but also the entry of circulating 
neutrophils, monocytes and lymphocytes to the injured site, directly impacting on neuronal survival 
and death (as reviewed in [40]). Increased ICP is thought to be one of the major factors determining 
mortality and morbidity after TBI. 
Over the last 25 years research into therapeutic interventions for brain trauma has evolved from 
attempts to reduce ICP to attempts to interfere with the underlying pathophysiological mechanisms. 
Most significantly, recent experimental work has provided evidence for involvement of the kallikrein-
kinin system in the progression of edema [41]. In addition, experimental models of CNS injury have 
determined that bradykinin induces the release of glutamate and aspartate as well as being a potent 
endothelium-dependant dilator of the brain vasculature [42,43]. Thus, it is not surprising that a 
significant amount of research has focused on the multifactorial involvement of bradykinin in the 
secondary phase of TBI. Bradykinin levels were significantly increased at 2 hours following controlled 
cortical impact before declining over subsequent hours [44]. Moreover, in regards to the mRNA levels 
of B1 and B2 receptors, expression of the B1 receptor mRNA was increased four-fold at 6 hours after 
controlled cortical impact injury, although mRNA levels for the B2 receptor did not increase 
significantly [45]. These results are not surprising given that B1 expression is induced whereas B2 is 
constitutive expressed.  




Further confirmation for the role of bradykinin and its receptors in TBI has been obtained through 
the use of genetically engineered mice that are deficient for either bradykinin B1 or B2 receptors. B2 
receptor-null animals had 50% less brain water content following injury than wild-type animals and 
performed better on functional outcome tests [44]. In contrast, another study reported that B2 receptor-
null mice had an improved neurological outcome but no difference in brain edema, although it may be 
possible that up-regulation of another compensatory pathway may have occurred in response to the B2 
receptor being genetically absent. In addition, both B2 receptor-null animals and animals treated with a 
B2 receptor antagonist had decreased accumulation of neutrophils 24 hours post-TBI as well as 
reduced iNOS mRNA levels. Furthermore, contusions in B2 receptor-null mice were significantly 
smaller than wild-type and B1 receptor-null animals [46]. The authors concluded that detrimental 
effects of bradykinin after TBI are mainly mediated through B2 receptors on cerebral vessels, the 
cerebrovascular effect, driving the formation of brain edema, vasodilation, and/or changes in cerebral 
blood flow.  
Nonetheless, a role for B1 receptors in the genesis of edema has also been recently suggested. In a 
murine model of experimental cryolesion, B1 receptor-null animals were reported to have smaller 
lesions with reduced BBB dysfunction and edema formation [47]. Additionally, the therapeutic 
treatment of wild-type mice with the B1 receptor inhibitor, R-715, mirrored the results obtained from 
the knockout studies. The authors failed to find similar neuroprotection when the B2 receptor was 
knocked out or inhibited therapeutically. This study is contradictory to much of the previous literature, 
and the authors themselves conclude that the contradictions may be due to the different model which 
they employed to study this phenomenon. In any case, these collective observations suggest a 
detrimental role for bradykinin receptors in TBI and provide compelling evidence that therapeutic 
inhibition of these receptors may be beneficial for outcome of patients following TBI. 
 The first experimental TBI studies utilizing a B2 receptor antagonist used aprotinin, a non-specific 
kallikrein inhibitor, to therapeutically target the vasogenic edema produced from cortical cold lesion in 
rabbits [48]. However, prior to the development of a non-peptide bradykinin antagonist, these 
compounds were plagued with low potency and poor in vivo stability [49]. The first non-peptide 
bradykinin B2 receptor antagonist, CP-0127, revealed no significant toxicity in pre-clinical animal 
toxicity or phase I human volunteer studies [49]. Anatibant® (LF 16-0687 Ms), another non-peptide B2 
receptor antagonist, has also been trialed in experimental TBI. Rats subject to closed head injury had 
reduced brain edema at 24 hours as well as improved neurological function at day 3 and 7 following 
Anatibant® infusion administered from 1 to 24 hours post-injury [50]. Furthermore, experimental rat 
models of both cryolesion and controlled cortical impact have shown Anatibant® to reduce brain 
edema [41,51]. Along with this reduction in brain edema, Anatibant® treatment also reduced ATP 
breakdown products hypoxanthine and xanthine [41]. These products are formed following injury, 
especially in times of limited oxygen, and contribute to the production of potentially harmful free 
radicals. In addition, administration of Anatibant® 30 minutes after diffuse injury reduced neurological 
deficit by 26% and brain edema by 22% [46]. In agreement with Hellal and colleagues [46], Ongali  
et al. [45] reported that subcutaneous treatment with Anatibant® 30 minutes post-injury significantly 
reduced BBB permeability at 4 hours. However Anatibant® may need to be administered almost 
immediately after injury, as after cryolesion injury there was no effect if given 30 to 60 minutes post-




injury [52]. Nonetheless when interpreting these results, one must take into account the different types 
of brain injury employed in these studies.  
Recently studies have utilized autoradiographic technology, not only to determine the brain regions 
where B1 and B2 receptors are located normally, but also to determine the displacement of 
radioligands following treatment with the receptor antagonist Anatibant® [45]. This study showed the 
ability of Anatibant® to cross the normal BBB and displace the B2 receptor radioligand from various 
regions including the forebrain, basal ganglia and hindbrain. This displacement was present in all areas 
at 1 hour and persisted for up to 4 hours after the injection. Following disruption of the BBB by injury, 
Anatibant® is able to penetrate the brain more readily, which may account for its neuro- and vascular 
protective effects [45]. 
Following on from the promising experimental work, a single-dose, three-arm, placebo-controlled, 
phase I clinical study of Anatibant® in patients with severe TBI was published in 2005. During this 
trial Anatibant® was administered as a subcutaneous injection at either 3.75 mg or 22.5 mg. The 
authors reported that the drug was well tolerated in severe TBI patients with no unexpected adverse 
outcomes, with the recommendation to begin phase II trials to determine a dose-response [53]. 
Unfortunately, the phase II placebo controlled trial was abandoned after collecting data from just over 
half the number of patients in the planned sample size [54]. Of 163 patients treated with Anatibant®, 43 
were reported to have adverse events within 14 days of treatment compared to 11 of the 57 placebo 
patients. A response letter was written by the drug company involved suggesting the study conditions 
were flawed with inadequate guidelines given to investigators [55]. In wake of this latest trial there is a 
cloud over whether Anatibant® has beneficial or detrimental effects on TBI patients.  
Other clinical trials utilizing bradykinin antagonists have been more successful. In a randomized, 
single-blinded study in head injured patients, CP-0127 performed well [54]. CP-0127 was reported to 
prevent the pathological rise in ICP and the subsequent neurological deterioration, thereby reducing 
the need for surgical intervention or manipulation of ICP. However, the trial was conducted on a 
highly selective group of patients with focal lesions. Another more robust phase II prospective, 
randomized, double-blinded clinical study was presented in 1999 where Bradycor™ (deltibant, CP-
1027) or placebo was administered as a continuous 5-day infusion, beginning within 12 hours of injury 
[56]. Patients were followed for the first 14 days of their hospital stay and then followed up at 3 and 6 
months post-injury. Bradycor™ was well tolerated with no adverse events attributable to the 
compound. Importantly, there were positive trends reported for ICP, therapy intensity level, 
neuropsychological tests both during the initial stay and at the 3- and 6- month follow ups [55]. Whilst 
these clinical trials provide encouraging evidence that bradykinin receptor antagonists may potentially 
afford neuroprotection in TBI, it should be noted that safety and efficacy of B2 receptor antagonists 
have not been reliably ascertained and more work needs to be undertaken using well organized, 
randomized clinical trials [57]. 
When considering mechanisms of action, one should not dismiss the fact that bradykinin potentiates 
the release of the tachykinin SP, which has been recently implicated as a critical factor in the formation 
of post-traumatic edema [29,58,59]. Statistically higher levels of SP have been detected in the blood 30 
minutes port-injury before declining back to sham levels by 5 hours [58]. It is thought that this SP is 
released in the vicinity of the vasculature by mechanical stretch of the perivascular neurons before 
entering the bloodstream [60]. This perivascular release has been postulated to be associated with the 




early, but transient, opening of the BBB and the subsequent formation of vasogenic edema. Notably, 
both bradykinin and SP can be modulated by angiotensin-converting enzyme (ACE), through its 
involvement in their degradation. ACE breaks down hydrolytic bonds in such a way that kinins are 
unable to bind to their receptor [61]. Indeed, recently it was shown that treatment with the ACE 
inhibitor Captopril further increased SP immunoreactivity in injured brain at 5 hours after TBI and 
resulted in significantly worsened outcome [62]. To ensure this was a class effect a second ACE 
inhibitor, Enalapril, was also administered and shown to produce similar effects.  
The role of SP in post-traumatic vasogenic edema formation has recently been studied utilizing 
diffusion weighted magnetic resonance (MR) imaging [63]. These studies reported that in a model of 
diffuse axonal injury in rats, TBI increased the apparent diffusion coefficient reflecting the increased 
diffusion distance of water related to vasogenic edema. Notably, when animals were pre-treated with 
capsaicin, a compound that depletes neuropeptides including SP, the apparent diffusion coefficient was 
lowered [63]. Accordingly, capsaicin treatment resulted in a profound reduction in edema at 5 hours 
post-injury as well as reduced BBB permeability and improved motor and cognitive outcome. 
Furthermore, another set of studies using magnetic resonance spectroscopy demonstrated that 
administration of an NK1 antagonist increased brain free magnesium concentration [64], which has 
previously been shown to be strongly associated with outcome after TBI [65]. The NK1 antagonist 
also reduced edema as measured by MR imaging plus wet weight/dry weight analysis, reduced BBB 
permeability and improved functional outcome [58,66]. The data therefore confirm that the release of 
neuropeptides in the form of neurogenic inflammation play a critical role in the secondary events 
associated with TBI. 
4. Spinal Cord Injury 
SCI, like TBI, involves both primary and secondary mechanisms of injury. Of particular interest is 
blood spinal cord barrier (BSCB) disruption, which is associated with the development of profound 
post-traumatic edema that leads to functional deficits. The BSCB exists at the capillary level and 
regulates the molecules that can enter the spinal cord tissue. Electron microscopy has demonstrated 
that in the BSCB the endothelial cells connected by tight junctions are surrounded by a think basement 
membrane, as observed in the BBB of the brain [67]. Thus, the BSCB resembles the BBB in many 
ways, not only in function but also structurally [67–69]. It has been well established that BSCB 
disruption [70,71] and edema formation [69,72–76] occur following SCI. Furthermore, such processes 
have been associated with a worsening of function, whilst restoration of the BSCB improved 
functional outcome [77,78]. Thus the development of pharmacological intervention that reduce BSCB 
disruption is of utmost importance.  
As mentioned earlier, the kallikrein-kinin system has been implicated in posttraumatic vascular 
injury of the CNS and in vasogenic edema. In the spinal cord, kininogen and its conversion to 
vasoactive kinins significantly increased following a weight drop model of SCI in rats [79]. Therefore 
it is not surprising that the kallikrein-kinin system has also been targeted for the development 
pharmacological intervention following SCI. Like in TBI, bradykinin has been implicated in the 
disruption of the BSCB observed following SCI. Furthermore, pre-treatment with a B2 receptor 
antagonist (B9430) significantly reduced BSCB disruption immediately following a bilateral 




compression model of SCI [80]. Similarly, Sharma and colleagues found that pre-treatment with the 
B2 receptor antagonist HOE-140 significantly reduced BSCB permeability following a focal model of 
SCI [81]. These investigations clearly demonstrate that bradykinin is involved in the disruption of the 
BSCB following trauma. However, two phases of BSCB disruption have been observed, one 
immediately following SCI and the second at 72 hours post-injury [80]. Whilst the B9430 was able to 
attenuate BSCB disruption immediately following injury, there was no significant difference at the 72 
hour time point. It is well known that bradykinin has a short half-life [82] and that its concentration 
begins to fall quite quickly following an initial tissue insult [19]. This suggests that other mediators 
may play more important roles at these later time points.  
One candidate for this later disruption of the BSCB is SP, although at present, no such research has 
investigated the role of SP in neurogenic inflammation following SCI. However, SCI causes changes 
in SP expression within the spinal cord. Following a focal model of SCI a significant increase in the 
content of SP was observed at both 1 and 2 hours [76]. This result was detected not only in the injured 
spinal segment but also in the samples removed 5 mm proximal and distal to the lesion [83]. In 
contrast, a decrease in SP has also been observed at both 5 hours [83] and later at 7 days post-SCI [84]. 
In a transection model of SCI, the level of SP immunoreactivity was increased at 5 days, 2, 5, 8 and 12 
weeks post injury [85]. The differences in SP expression following injury may simply be due to the 
different injury models employed, although further investigation is required to clarify the issue. 
In addition to alterations in SP, concurrent changes in NK1 receptor expression have also been 
noted. At 1 week following a thoracic spinal cord transection, a significant increase of NK1 below the 
injury site within the dorsal horn and lamina X was observed [86]. This increase may correlate with the 
previously demonstrated increased SP within these regions following a transection injury [85]. Vita 
and colleagues further demonstrated an increase of NK1 receptors within the ventral horn above the 
injury site, which again correlates with previously reported SP increases [87]. Furthermore, at the 
cervical level a significant increase of NK1 density was also observed at 1 week post-injury within 
some lamina of the dorsal horn. This increase in receptor density has not been matched by previous 
studies, where no increase or even a decrease in SP content has been observed [85]. 
Further confirmation for a role of SP in BSCB dysfunction and genesis of edema following SCI has 
been indirectly obtained by examining the effects of naloxone [76,84]. Administration of naloxone, an 
opiate antagonist, has been shown to significantly reduce the development of edema [76], increase 
blood flow [88], reduce ischemia [89] and improve neurological function [84]. Naloxone treatment 
was most effective when it inhibited the kappa-opioid receptor [76,90]. Administration of a kappa-
opioid antagonist has also been demonstrated to improve neurological outcome following TBI [91]. It 
should be highlighted that stimulation of the kappa-opioid receptor facilitates the release of SP [92]. 
Accordingly, inhibition of kappa-opioid receptors can lead to a reduction in SP release [93], which in 
part, may account for the beneficial effects of naloxone and other kappa-opioid receptor antagonists in SCI. 
Finally, of particular interest is the fact that the changes in SP expression are observed at later time 
points, supporting the proposition that SP may play an important role in mediating injury at later time 
points, or indeed both at early and late time points. Thus, it may be that whilst bradykinin is involved 
in the early development of neurogenic inflammation, such processes are then potentiated through 
bradykinin mediated release of SP.  




5. Ischemic Stroke 
Ischemic stroke results from a disturbance of the blood supply to the brain caused by a blockage 
due to either thrombosis or an embolism. This reduction or loss of blood flow results in cerebral tissue 
becoming hypoxic, and the initiation of secondary injury mechanisms that over time, cause neuronal 
cell death and neurological deficits. Thus restoration of blood flow to the brain is of upmost 
importance. To date, the only clinical treatment available for ischemic stroke is the intravenous 
administration of tissue-type plasminogen activator (tPA), which breaks down clots to restore normal 
blood flow. Unfortunately, not only does the restoration of blood flow also initiate reperfusion related 
injury mechanisms, tPA must be administered within 4.5 hours of symptom onset [94]. Thus the search 
for novel neuroprotective agents that may reduce both hypoxic and reperfusion injury continues. 
Bradykinin and the tissue kallikrein-kinin system have been implicated in ischemic injury both in 
the periphery and in the CNS, where it plays a critical role in cell death by potentiating 
neuroinflammation, vasodilation and increasing vascular permeability resulting in edema. In ischemic 
stroke both kallidin and bradykinin expression are increased early. In experimental models of ischemic 
stroke bradykinin levels were elevated during the first 24 hours following reperfusion with maximal 
expression at 12 hours [95]. However, bradykinin returns to normal levels by 24 hours, suggesting that 
the rise occurs early but is not sustained. In contrast, in human ischemic stroke bradykinin levels were 
similar to that of controls, although plasma kallidin levels were increased at 24 hours and remained 
elevated for the subsequent week [96]. However the earliest time point studied was 24 hours, and 
therefore the rise in bradykinin may have been missed. These results suggest a role for the tissue-
kallidin system in potentiating injury during ischemia/reperfusion. Indeed in animal models of cerebral 
ischemia, tissue bradykinin levels show a marked correlation with tissue injury and brain swelling [97].  
Along with the increase in bradykinin and kallidin levels, there is a concurrent increase in 
bradykinin receptors B1 and B2. This increase in receptor expression has been observed as early as 4 
hours and was still apparent at 24 hours following reperfusion [95]. Interestingly, the receptors showed 
different patterns of expression, with B2 receptors primarily found on neurons, whereas B1 receptors 
were expressed on astrocytes in the ischemic penumbra. Moreover, in a murine model of ischemic 
stroke, the expression of B1 receptor mRNA was substantially greater than B2 receptor mRNA 
expression at 24 hours post-injury [98]. This differential pattern of expression suggests that these 
receptors modulate different aspects of ischemic injury [99], and potentially both B1 and B2 receptor 
antagonists may provide protection in ischemic stroke.  
The predominant expression of B2 receptors on neurons has led much of the research on 
neuroprotection in ischemic stroke to focus on antagonism of the B2 receptor, which has provided 
substantial protection in animal models of ischemic stroke. Continuous or multiple systemic 
administration of the B2 antagonists CP-0597 and LF 16-0687 Ms, following transient middle cerebral 
artery occlusion (MCAO) reduced edema and infarct size and improved behavioral deficits [21,100]. 
Notably, low doses of LF 16-087 demonstrated greater neuroprotection than higher doses, which the 
authors postulated could be due to depression of cholinergic transmission or increase in B1 receptor 
expression due to prolonged blocking of B2 receptors [21]. However, it was recently shown that the 
long acting B2 antagonist, bradyzide, reduced the expression of B1 receptors [99], which argues 
against long term B2 inhibition increasing the effects of the B1 mediated injury pathway. This study 




also demonstrated that bradyzide, had greater neuroprotective efficacy than the B1 receptor antagonist, 
SSR240612, as it maintained BBB integrity by protecting endothelial cells and tight junctions. Along 
with protection of the BBB, bradyzide reduced the release of pro-inflammatory cytokines and 
improved neurological outcome [99]. Further confirmation that the B2 receptor plays a critical role in 
ischemic injury is that B2 receptor knockout mice had reduced infarct size and brain water content, 
resulting in an improvement in function [95].  
In contrast to these studies, Austinat and colleagues showed that the absence or antagonism of the 
B1 receptor provided greater neuroprotection than inhibition of B2 receptors in ischemic injury [98]. In 
this study, B1 receptor-null mice that underwent transient MCAO had approximately a 30% reduction 
in infarct size. This was deemed to be functionally relevant as B1 receptor-null mice had improved 
neurological and motor outcome compared to wild type mice, and in addition had reduced edema 
formation and IL-1β production at 24 hours. The role of B1 receptors in ischemic injury was 
confirmed by treating wild type mice with the B1 receptor antagonist, R-715, which produced similar 
protection and improvement in function to the B1 receptor-null mice. In contrast to the above, B2 
receptor-null mice and treatment with the B2 antagonist, Hoe-140, did not afford protection in 
ischemia, suggesting that ischemic injury was mainly mediated by B1 receptors. Interestingly, 
bradyzide, which provided greater protection than the B1 receptor antagonist, SSR240612, also 
reduced the expression of B1 receptors [99]. Thus the greater efficacy produced by this antagonist may 
be due to its ability to reduce both B1 and B2 mediated injury cascades. These results confirm that 
bradykinin plays an integral role in early ischemic injury and that both B1 and B2 receptor antagonists 
may represent novel neuroprotective therapies in ischemic stroke. 
Despite the early detrimental effects of bradykinin and their receptors in ischemic stroke, treatment 
with bradykinin antagonists may still be beneficial for longer-term neuronal survival through ischemic 
post-conditioning. Ischemic post-conditioning is a relatively new phenomenon and is defined as a 
“sublethal stimuli or insult performed immediately or up to 2 days after cerebral ischemia” which 
affords neuroprotection to vulnerable neurons [101]. The mechanisms by which post-conditioning 
protect neurons remains relatively unknown. However original studies used interruptions to 
reperfusion to induce post-conditioning, implying that changes in cerebral blood flow and consequent 
changes in BBB integrity and inflammation are involved (for review, see [101]). Bradykinin plays an 
integral role in cerebral blood flow, barrier function and inflammation and therefore bradykinin in 
addition to other modes of post-conditioning such as treatment with norepinephrine or 3-nitropropionic 
acid or another short ischemic insult, are neuroprotective in ischemic stroke [102,103]. 
Indeed, gene transfer treatment using the adenovirus carrying the human tissue Kallikrein gene 
promoted cell survival, angiogenesis, neurogenesis and gliosis in the penumbra both immediately [104] 
and at 8 hours following ischemia/reperfusion injury [105]. Furthermore, bradykinin by binding to 
both B1 and B2 receptors causes the release of NO [106]. The production of NO during the later stages 
of stroke may be beneficial to neurons as it can scavenge superoxide radicals, and promote 
proliferation of both neurons and endothelial cells [105]. Further post-conditioning studies have shown 
that treatment with bradykinin as late as 2 days following the initial ischemic insult provided 
neuroprotection for the particularly vulnerable CA1 hippocampal neurons. Post-conditioning by 
bradykinin regulated antioxidant enzymes expression, superoxide dismutase and catalase, and 
protected mitochondria by reducing oxidative stress and subsequent cell death [107]. It has been 




suggested that the B2 receptor may play an integral role in this protective effect of bradykinin as B2 
receptor-null mice had larger infarct sizes, and greater neurological deficits and mortality [108]. 
However, the validity of this study has been questioned [109] and no other studies have reported that a 
lack of B2 receptor is detrimental in ischemic stroke. 
Bradykinin has also been shown to possess anti-inflammatory properties as it inhibited LPS induced 
TNF-α and IL-1β release from microglia in vitro [13]. The authors postulated that bradykinin 
modulated microglial function by increasing prostaglandin synthesis, resulting in greater microglial 
cAMP production and a negative feedback for cytokine production. Overall however, bradykinin may 
be beneficial following ischemic stroke if administered at the later stages, while in the early stages it is 
particularly detrimental as it induces both an inflammatory response and neurogenic inflammation. 
Furthermore, its ability to increase SP release is likely to further contribute to ischemic injury in a 
similar mechanism as is seen in TBI and SCI.  
Despite the detrimental role of SP in CNS injury, little research has been undertaken to date on the 
role of SP in ischemic stroke. It is known that SP release is increased during an ischemic insult in both 
animal models and clinical stroke. In transient MCAO, SP expression was increased at 24 hours post-
reperfusion, with this increase particularly apparent in perivascular, neuronal and glial tissue within the 
penumbra [110]. As previously discussed SP, like bradykinin, initiates neurogenic inflammation 
resulting in increased vascular permeability, plasma extravasation and subsequent genesis of edema. 
Accordingly, the rise in SP expression was associated with edema formation [110]. Interestingly in the 
clinic, transient ischemic attacks produced a greater increase in serum SP levels in than in complete 
stroke, although both transient and complete stroke resulted in higher serum SP levels than control 
patients [111]. These results suggest that SP is an important modulator of ischemic injury and may be 
particularly integral to reperfusion injury, which is known to contribute to neuronal cell death. During 
a stroke, blood flow is limited for a period of time causing cerebral tissue to become hypoxic. In an  
in vitro model of hypoxia, SP release was increased in the carotid body, in a Ca2+ dependent manner 
[112]. The carotid bodies are the major peripheral chemoreceptors, which detect changes in partial 
pressure of oxygen in arterial blood, then relay signals to the brain stem to instigate the required 
changes to improve oxygenation to the brain. Thus carotid bodies and SP may be integrally involved in 
ischemic stroke where there is both hypoxia and reperfusion injury. Therefore inhibiting SP effects 
may be beneficial.  
Indeed, intracerebral ventricular administration of the potent NK1 antagonist, SR140333, 
significantly reduced infarct volume and improved functional deficits at 24 hours following focal 
ischemia in the rat [113]. Similar findings have also been reported in a transient model of focal 
ischemia in rats where intravenous administration of an NK1 antagonist was shown to reduce edema 
formation and significantly improve functional outcome [114]. In addition, in myocardial ischemia, 
treatment with the NK1 antagonist L-703,606 reduced post-reperfusion ischemic injury in the hearts of 
magnesium deficient rats [115]. A magnesium deficient diet in these animals is known to induce 
neurogenic inflammation with associated increases in SP and proinflammatory cytokines [116]. These 
results suggest that administration of a NK1 antagonist during ischemic injury may provide a novel 
avenue for neuroprotection following ischemic stroke.  
 





Kinins, and particularly bradykinin and SP, play an integral role in the injury processes that occur 
following TBI, SCI and ischemic stroke. This review has focused on their ability to induce neurogenic 
inflammation resulting in vasodilation, plasma extravasation and genesis of edema, while indicating 
that they have modulatory effects on a number of other secondary injury factors include excitotoxicity, 
oxidative stress, and ion gradients. Moreover, kinins are potent pro-inflammatory mediators by binding 
to their respective receptors located on all CNS inflammatory cells. Both neuroinflammation and 
edema are integral to the progressive secondary injury mechanisms that lead to the development of 
neurological deficits. Thus kinin receptor antagonists may represent novel neuroprotective agents for 
the treatment of CNS injury. 
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